BioSpace News Archive

Under terms of the deal, Gilead can advance up to five targets identified through this collaboration and will be responsible for chemistry and development against these targets.

Janssen Pharmaceuticals presented data that showed its RNAi therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually.

Axsome Therapeutics, based in New York City, announced that its AXS-05 met its primary endpoint for smoking cessation treatment. The drug significantly reduced daily smoking compared to patients on bupropion.

The life science industry is continually making advancements in every area! We want to know what cool science innovations are currently in progress and the professionals behind them.

Novartis will use a priority review voucher to expedite review of the treatment that could hit blockbuster status within two years of launching.

April 17, 2019 is the 29th World Hemophilia Day, a designated day to create awareness of the disease. Hemophilia is one of a number of bleeding disorders. The blood of people with hemophilia does not clot normally as the result of insufficient clotting factor. As a result, they can bleed for a longer time.

One week after the U.S. Food and Drug Administration approved Amgen’s Evenity, the California-based company has set the list price for the medication at $21,900.

There has been significant progress in so-called bioprinting—using a type of 3D printing to manufacture biological tissues. But an actual organ hadn’t been accomplished—until now.

This week, a researcher with The Institute of Cancer Research (ICR), London, and the Royal Marsden NHS Foundation Trust published research that showed another mechanism for how colon cancer cells hide from the immune system. They published their work in the Journal of ImmunoTherapy of Cancer.

The vast majority of immune cells are found in the gut but historically, the gut has been viewed as a liability to drug development. The question of whether or not greater understanding of harnessing the gut could drive more promising drug development has led to the formation of a new company, Kintai Therapeutics.